Trials / Recruiting
RecruitingNCT07187973
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Disc Medicine, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DISC-3405 | DISC-3405 is administered subcutaneously. |
Timeline
- Start date
- 2026-01-06
- Primary completion
- 2027-06-01
- Completion
- 2027-10-01
- First posted
- 2025-09-23
- Last updated
- 2026-03-31
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07187973. Inclusion in this directory is not an endorsement.